Loading…

Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy

Background: Combination antiretroviral therapy (cART) is associated with lipodystrophy (lipoatrophy and lipoaccumulation) and several metabolic abnormalities that together can contribute to an increased cardiovascular risk. The aim of this study was to evaluate the prevalence of obesity in patients...

Full description

Saved in:
Bibliographic Details
Published in:Journal of endocrinological investigation 2012-12, Vol.35 (11), p.964-970
Main Authors: Freitas, P., Carvalho, D., Santos, A. C., Matos, M. J., Madureira, A. J., Marques, R., Martinez, E., Sarmento, A., Medina, J. L.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c303t-1f33e8a792e12c62d071e2dc02d212e3ab7366351c31f739934afcd68fe971313
cites cdi_FETCH-LOGICAL-c303t-1f33e8a792e12c62d071e2dc02d212e3ab7366351c31f739934afcd68fe971313
container_end_page 970
container_issue 11
container_start_page 964
container_title Journal of endocrinological investigation
container_volume 35
creator Freitas, P.
Carvalho, D.
Santos, A. C.
Matos, M. J.
Madureira, A. J.
Marques, R.
Martinez, E.
Sarmento, A.
Medina, J. L.
description Background: Combination antiretroviral therapy (cART) is associated with lipodystrophy (lipoatrophy and lipoaccumulation) and several metabolic abnormalities that together can contribute to an increased cardiovascular risk. The aim of this study was to evaluate the prevalence of obesity in patients on cART according to the presence of clinical lipodystrophy (CL) and to analyze factors associated with obesity. Methods: We evaluated 368 HIV-infected adults on cART. Results: CL was present in 59.0%. Independently of gender, patients with CL were more frequently underweight [5.7% (21/368)] and of normal weight [47.3% (174/368)], and less frequently overweight [33.2% (122/368)] or obese [13.9% (51/368)]. Mean body mass index was higher in patients with abdominal prominence regardless of the presence of clinical lipoatrophy. Patients with CL had lower waist circumference, higher waist/hip and fat mass ratio and lower total and subcutaneous fat, without significant difference in visceral fat but with a higher visceral/subcutaneous fat ratio, as evaluated by CT at abdominal level. CL was significantly less frequent in overweight [odds ratio (OR)=0.21, 95% confidence interval (CI): 0.05–0.92] and obese (OR=0.05, 95%CI: 0.01–0.26) patients, when compared to underweight ones, independent of age, gender, duration of infection, cART regimen, virological suppression, and HIV-infection risk factor. Conclusions: Being overweight or obese is highly prevalent in HIV-infected patients on cART. Patients with CL were more frequently under- or normal weight, and less frequently overweight or obese. Obesity is a condition that should be considered in HIV patients on cART.
doi_str_mv 10.3275/8187
format article
fullrecord <record><control><sourceid>pubmed_sprin</sourceid><recordid>TN_cdi_pubmed_primary_22186163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>22186163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c303t-1f33e8a792e12c62d071e2dc02d212e3ab7366351c31f739934afcd68fe971313</originalsourceid><addsrcrecordid>eNo1kMFOAjEURRujEQR_wXTjcrTtg2lnaYgCCYku1O2ktG-kZGgnbSGZv3cIunqLe-7NyyFkytkTCDl_VlzJKzLmUrBCgSqvyZhBxYsZq-SI3KW0ZwwkKHlLRkJwVfISxuT0EfGkW_QGaWho2GJyuafaW-pyohFbnV3waec6mgM1rfPO6Ja2rgu2TzmGbtdT5-lq_V0436DJaKm2x3ZoBz8MZVdEHLiTi0Mv7zDqrp-Sm0a3Ce__7oR8vb1-LlbF5n25XrxsCgMMcsEbAFRaVgK5MKWwTHIU1jBhBRcIeiuhLGHODfBGQlXBTDfGlqrBSnLgMCEPl93uuD2grbvoDjr29b-AAXi8AGmI_A_Geh-O0Q8_1ZzVZ7H1WSz8Atb5aQs</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy</title><source>Springer Nature</source><creator>Freitas, P. ; Carvalho, D. ; Santos, A. C. ; Matos, M. J. ; Madureira, A. J. ; Marques, R. ; Martinez, E. ; Sarmento, A. ; Medina, J. L.</creator><creatorcontrib>Freitas, P. ; Carvalho, D. ; Santos, A. C. ; Matos, M. J. ; Madureira, A. J. ; Marques, R. ; Martinez, E. ; Sarmento, A. ; Medina, J. L.</creatorcontrib><description>Background: Combination antiretroviral therapy (cART) is associated with lipodystrophy (lipoatrophy and lipoaccumulation) and several metabolic abnormalities that together can contribute to an increased cardiovascular risk. The aim of this study was to evaluate the prevalence of obesity in patients on cART according to the presence of clinical lipodystrophy (CL) and to analyze factors associated with obesity. Methods: We evaluated 368 HIV-infected adults on cART. Results: CL was present in 59.0%. Independently of gender, patients with CL were more frequently underweight [5.7% (21/368)] and of normal weight [47.3% (174/368)], and less frequently overweight [33.2% (122/368)] or obese [13.9% (51/368)]. Mean body mass index was higher in patients with abdominal prominence regardless of the presence of clinical lipoatrophy. Patients with CL had lower waist circumference, higher waist/hip and fat mass ratio and lower total and subcutaneous fat, without significant difference in visceral fat but with a higher visceral/subcutaneous fat ratio, as evaluated by CT at abdominal level. CL was significantly less frequent in overweight [odds ratio (OR)=0.21, 95% confidence interval (CI): 0.05–0.92] and obese (OR=0.05, 95%CI: 0.01–0.26) patients, when compared to underweight ones, independent of age, gender, duration of infection, cART regimen, virological suppression, and HIV-infection risk factor. Conclusions: Being overweight or obese is highly prevalent in HIV-infected patients on cART. Patients with CL were more frequently under- or normal weight, and less frequently overweight or obese. Obesity is a condition that should be considered in HIV patients on cART.</description><identifier>ISSN: 0391-4097</identifier><identifier>EISSN: 1720-8386</identifier><identifier>DOI: 10.3275/8187</identifier><identifier>PMID: 22186163</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Anti-HIV Agents - therapeutic use ; Body Composition ; Body Mass Index ; CD4 Lymphocyte Count ; Cross-Sectional Studies ; Endocrinology ; Female ; HIV-1 - isolation &amp; purification ; HIV-Associated Lipodystrophy Syndrome - complications ; HIV-Associated Lipodystrophy Syndrome - drug therapy ; Humans ; Logistic Models ; Male ; Medicine ; Medicine &amp; Public Health ; Metabolic Diseases ; Obesity - virology ; Original Articles ; Portugal ; RNA, Viral - blood ; Waist Circumference ; Waist-Hip Ratio</subject><ispartof>Journal of endocrinological investigation, 2012-12, Vol.35 (11), p.964-970</ispartof><rights>Italian Society of Endocrinology (SIE) 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c303t-1f33e8a792e12c62d071e2dc02d212e3ab7366351c31f739934afcd68fe971313</citedby><cites>FETCH-LOGICAL-c303t-1f33e8a792e12c62d071e2dc02d212e3ab7366351c31f739934afcd68fe971313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22186163$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Freitas, P.</creatorcontrib><creatorcontrib>Carvalho, D.</creatorcontrib><creatorcontrib>Santos, A. C.</creatorcontrib><creatorcontrib>Matos, M. J.</creatorcontrib><creatorcontrib>Madureira, A. J.</creatorcontrib><creatorcontrib>Marques, R.</creatorcontrib><creatorcontrib>Martinez, E.</creatorcontrib><creatorcontrib>Sarmento, A.</creatorcontrib><creatorcontrib>Medina, J. L.</creatorcontrib><title>Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy</title><title>Journal of endocrinological investigation</title><addtitle>J Endocrinol Invest</addtitle><addtitle>J Endocrinol Invest</addtitle><description>Background: Combination antiretroviral therapy (cART) is associated with lipodystrophy (lipoatrophy and lipoaccumulation) and several metabolic abnormalities that together can contribute to an increased cardiovascular risk. The aim of this study was to evaluate the prevalence of obesity in patients on cART according to the presence of clinical lipodystrophy (CL) and to analyze factors associated with obesity. Methods: We evaluated 368 HIV-infected adults on cART. Results: CL was present in 59.0%. Independently of gender, patients with CL were more frequently underweight [5.7% (21/368)] and of normal weight [47.3% (174/368)], and less frequently overweight [33.2% (122/368)] or obese [13.9% (51/368)]. Mean body mass index was higher in patients with abdominal prominence regardless of the presence of clinical lipoatrophy. Patients with CL had lower waist circumference, higher waist/hip and fat mass ratio and lower total and subcutaneous fat, without significant difference in visceral fat but with a higher visceral/subcutaneous fat ratio, as evaluated by CT at abdominal level. CL was significantly less frequent in overweight [odds ratio (OR)=0.21, 95% confidence interval (CI): 0.05–0.92] and obese (OR=0.05, 95%CI: 0.01–0.26) patients, when compared to underweight ones, independent of age, gender, duration of infection, cART regimen, virological suppression, and HIV-infection risk factor. Conclusions: Being overweight or obese is highly prevalent in HIV-infected patients on cART. Patients with CL were more frequently under- or normal weight, and less frequently overweight or obese. Obesity is a condition that should be considered in HIV patients on cART.</description><subject>Anti-HIV Agents - therapeutic use</subject><subject>Body Composition</subject><subject>Body Mass Index</subject><subject>CD4 Lymphocyte Count</subject><subject>Cross-Sectional Studies</subject><subject>Endocrinology</subject><subject>Female</subject><subject>HIV-1 - isolation &amp; purification</subject><subject>HIV-Associated Lipodystrophy Syndrome - complications</subject><subject>HIV-Associated Lipodystrophy Syndrome - drug therapy</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metabolic Diseases</subject><subject>Obesity - virology</subject><subject>Original Articles</subject><subject>Portugal</subject><subject>RNA, Viral - blood</subject><subject>Waist Circumference</subject><subject>Waist-Hip Ratio</subject><issn>0391-4097</issn><issn>1720-8386</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNo1kMFOAjEURRujEQR_wXTjcrTtg2lnaYgCCYku1O2ktG-kZGgnbSGZv3cIunqLe-7NyyFkytkTCDl_VlzJKzLmUrBCgSqvyZhBxYsZq-SI3KW0ZwwkKHlLRkJwVfISxuT0EfGkW_QGaWho2GJyuafaW-pyohFbnV3waec6mgM1rfPO6Ja2rgu2TzmGbtdT5-lq_V0436DJaKm2x3ZoBz8MZVdEHLiTi0Mv7zDqrp-Sm0a3Ce__7oR8vb1-LlbF5n25XrxsCgMMcsEbAFRaVgK5MKWwTHIU1jBhBRcIeiuhLGHODfBGQlXBTDfGlqrBSnLgMCEPl93uuD2grbvoDjr29b-AAXi8AGmI_A_Geh-O0Q8_1ZzVZ7H1WSz8Atb5aQs</recordid><startdate>20121201</startdate><enddate>20121201</enddate><creator>Freitas, P.</creator><creator>Carvalho, D.</creator><creator>Santos, A. C.</creator><creator>Matos, M. J.</creator><creator>Madureira, A. J.</creator><creator>Marques, R.</creator><creator>Martinez, E.</creator><creator>Sarmento, A.</creator><creator>Medina, J. L.</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20121201</creationdate><title>Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy</title><author>Freitas, P. ; Carvalho, D. ; Santos, A. C. ; Matos, M. J. ; Madureira, A. J. ; Marques, R. ; Martinez, E. ; Sarmento, A. ; Medina, J. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c303t-1f33e8a792e12c62d071e2dc02d212e3ab7366351c31f739934afcd68fe971313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anti-HIV Agents - therapeutic use</topic><topic>Body Composition</topic><topic>Body Mass Index</topic><topic>CD4 Lymphocyte Count</topic><topic>Cross-Sectional Studies</topic><topic>Endocrinology</topic><topic>Female</topic><topic>HIV-1 - isolation &amp; purification</topic><topic>HIV-Associated Lipodystrophy Syndrome - complications</topic><topic>HIV-Associated Lipodystrophy Syndrome - drug therapy</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metabolic Diseases</topic><topic>Obesity - virology</topic><topic>Original Articles</topic><topic>Portugal</topic><topic>RNA, Viral - blood</topic><topic>Waist Circumference</topic><topic>Waist-Hip Ratio</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Freitas, P.</creatorcontrib><creatorcontrib>Carvalho, D.</creatorcontrib><creatorcontrib>Santos, A. C.</creatorcontrib><creatorcontrib>Matos, M. J.</creatorcontrib><creatorcontrib>Madureira, A. J.</creatorcontrib><creatorcontrib>Marques, R.</creatorcontrib><creatorcontrib>Martinez, E.</creatorcontrib><creatorcontrib>Sarmento, A.</creatorcontrib><creatorcontrib>Medina, J. L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of endocrinological investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Freitas, P.</au><au>Carvalho, D.</au><au>Santos, A. C.</au><au>Matos, M. J.</au><au>Madureira, A. J.</au><au>Marques, R.</au><au>Martinez, E.</au><au>Sarmento, A.</au><au>Medina, J. L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy</atitle><jtitle>Journal of endocrinological investigation</jtitle><stitle>J Endocrinol Invest</stitle><addtitle>J Endocrinol Invest</addtitle><date>2012-12-01</date><risdate>2012</risdate><volume>35</volume><issue>11</issue><spage>964</spage><epage>970</epage><pages>964-970</pages><issn>0391-4097</issn><eissn>1720-8386</eissn><abstract>Background: Combination antiretroviral therapy (cART) is associated with lipodystrophy (lipoatrophy and lipoaccumulation) and several metabolic abnormalities that together can contribute to an increased cardiovascular risk. The aim of this study was to evaluate the prevalence of obesity in patients on cART according to the presence of clinical lipodystrophy (CL) and to analyze factors associated with obesity. Methods: We evaluated 368 HIV-infected adults on cART. Results: CL was present in 59.0%. Independently of gender, patients with CL were more frequently underweight [5.7% (21/368)] and of normal weight [47.3% (174/368)], and less frequently overweight [33.2% (122/368)] or obese [13.9% (51/368)]. Mean body mass index was higher in patients with abdominal prominence regardless of the presence of clinical lipoatrophy. Patients with CL had lower waist circumference, higher waist/hip and fat mass ratio and lower total and subcutaneous fat, without significant difference in visceral fat but with a higher visceral/subcutaneous fat ratio, as evaluated by CT at abdominal level. CL was significantly less frequent in overweight [odds ratio (OR)=0.21, 95% confidence interval (CI): 0.05–0.92] and obese (OR=0.05, 95%CI: 0.01–0.26) patients, when compared to underweight ones, independent of age, gender, duration of infection, cART regimen, virological suppression, and HIV-infection risk factor. Conclusions: Being overweight or obese is highly prevalent in HIV-infected patients on cART. Patients with CL were more frequently under- or normal weight, and less frequently overweight or obese. Obesity is a condition that should be considered in HIV patients on cART.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>22186163</pmid><doi>10.3275/8187</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0391-4097
ispartof Journal of endocrinological investigation, 2012-12, Vol.35 (11), p.964-970
issn 0391-4097
1720-8386
language eng
recordid cdi_pubmed_primary_22186163
source Springer Nature
subjects Anti-HIV Agents - therapeutic use
Body Composition
Body Mass Index
CD4 Lymphocyte Count
Cross-Sectional Studies
Endocrinology
Female
HIV-1 - isolation & purification
HIV-Associated Lipodystrophy Syndrome - complications
HIV-Associated Lipodystrophy Syndrome - drug therapy
Humans
Logistic Models
Male
Medicine
Medicine & Public Health
Metabolic Diseases
Obesity - virology
Original Articles
Portugal
RNA, Viral - blood
Waist Circumference
Waist-Hip Ratio
title Prevalence of obesity and its relationship to clinical lipodystrophy in HIV-infected adults on anti-retroviral therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T14%3A02%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_sprin&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20obesity%20and%20its%20relationship%20to%20clinical%20lipodystrophy%20in%20HIV-infected%20adults%20on%20anti-retroviral%20therapy&rft.jtitle=Journal%20of%20endocrinological%20investigation&rft.au=Freitas,%20P.&rft.date=2012-12-01&rft.volume=35&rft.issue=11&rft.spage=964&rft.epage=970&rft.pages=964-970&rft.issn=0391-4097&rft.eissn=1720-8386&rft_id=info:doi/10.3275/8187&rft_dat=%3Cpubmed_sprin%3E22186163%3C/pubmed_sprin%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c303t-1f33e8a792e12c62d071e2dc02d212e3ab7366351c31f739934afcd68fe971313%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/22186163&rfr_iscdi=true